|
Aug 6
|
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
|
|
Aug 6
|
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
|
|
Aug 5
|
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update
|
|
Aug 5
|
$3.3 Bn Influenza Diagnostics Markets | Global Industry Analysis, Growth Trends, and Forecasts to 2032 - Shift to Point-of-Care Testing and Demand for Automated Molecular Kits Create Opportunities
|
|
Aug 4
|
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights
|
|
Aug 4
|
Trump Threatens Higher Tariff Rates on India Over Russian Oil
|
|
Aug 4
|
Hansa’s Idefirix shows potential as pre-treatment to Elevidys
|
|
Aug 4
|
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
|
|
Aug 4
|
Swiss Stocks Decline on US Tariffs, Push for Lower Drug Prices
|
|
Aug 4
|
Roche's first respiratory test powered by TAGS technology receives FDA clearance for SARS-CoV-2, Influenza A, Influenza B and RSV
|
|
Aug 4
|
Genentech reports five-year data from trial of Susvimo for wet AMD
|
|
Aug 4
|
Swiss Stocks Tumble as Trump's 39% Tariff Spooks Investors
|
|
Aug 3
|
Swiss Gird for Stocks to Fall as Markets Reopen After Tariff Hit
|
|
Aug 2
|
Illumina: Will big Pharma come to its rescue? Its CEO thinks so.
|
|
Aug 1
|
Genentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)
|
|
Aug 1
|
Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
|
|
Aug 1
|
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down
|
|
Aug 1
|
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
|
|
Aug 1
|
Switzerland, the land of luxury brands, could see prices skyrocket from Trump's 39% tariffs
|
|
Aug 1
|
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
|